About Autonomix Medical, Inc. Common Stock
https://autonomix.comAutonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals.
CEO
Bradley Hauser
Compensation Summary
(Year 2025)
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : C+
Price Target
Institutional Ownership
Summary
Showing Top 1 of 1
About Autonomix Medical, Inc. Common Stock
https://autonomix.comAutonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2026 | $0 | $7.53M ▲ | $-7.45M ▼ | 0% | $-1.38 ▼ | $-7.45M ▼ |
| Q1-2026 | $0 | $3.42M ▲ | $-3.34M ▼ | 0% | $-1.07 ▲ | $-3.33M ▼ |
| Q4-2025 | $0 | $3.2M ▲ | $-3.19M ▼ | 0% | $-1.81 ▼ | $-3.1M ▼ |
| Q3-2025 | $0 | $2.75M ▼ | $-2.71M ▲ | 0% | $-1.46 ▲ | $-2.62M ▲ |
| Q2-2025 | $0 | $2.84M | $-2.81M | 0% | $-2.47 | $-2.72M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2026 | $7.48M ▼ | $7.93M ▼ | $1.49M ▼ | $6.45M ▼ |
| Q1-2026 | $8.59M ▼ | $9M ▼ | $1.97M ▲ | $7.03M ▼ |
| Q4-2025 | $9.14M ▼ | $9.81M ▼ | $1.71M ▼ | $8.1M ▼ |
| Q3-2025 | $11.82M ▲ | $11.95M ▲ | $2.25M ▼ | $9.71M ▲ |
| Q2-2025 | $5.16M | $5.37M | $2.34M | $3.03M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2026 | $-3.34M | $-2.67M ▼ | $0 | $2.12M ▲ | $-547K | $-2.67M ▼ |
| Q1-2026 | $-3.34M ▼ | $-2.6M ▼ | $0 ▲ | $2.06M ▲ | $-547K ▲ | $-2.6M ▼ |
| Q4-2025 | $-3.19M ▼ | $-2.51M ▼ | $-4K ▲ | $-174K ▼ | $-2.69M ▼ | $-2.51M ▼ |
| Q3-2025 | $-2.71M ▲ | $-2.3M ▼ | $-5K ▼ | $8.97M ▲ | $6.67M ▲ | $-2.31M ▼ |
| Q2-2025 | $-2.81M | $-1.6M | $0 | $0 | $-1.6M | $-1.6M |
CEO
Bradley Hauser
Compensation Summary
(Year 2025)
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : C+
Price Target
Institutional Ownership
Summary
Showing Top 1 of 1